Literature DB >> 23400473

Mitotic control of cancer stem cells.

Monica Venere1, Tyler E Miller, Jeremy N Rich.   

Abstract

Cancer stem cells are self-renewing, tumorigenic cells at the apex of tumor hierarchies, and postulated to be quiescent in many tumor types. This issue of Cancer Discovery highlights a study that links the presentation of kinetochores within mitosis to an essential requirement for BUB1B/BubR1, broadening our understanding of the cell-cycle machinery in cancer stem cells.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23400473      PMCID： PMC3616319          DOI： 10.1158/2159-8290.CD-12-0588

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  10 in total

Review 1.  Coexistence of quiescent and active adult stem cells in mammals.

Authors:  Linheng Li; Hans Clevers
Journal:  Science       Date:  2010-01-29       Impact factor: 47.728

2.  Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs.

Authors:  Karen E Gascoigne; Stephen S Taylor
Journal:  Cancer Cell       Date:  2008-07-24       Impact factor: 31.743

3.  Aurora kinase B/C inhibition impairs malignant glioma growth in vivo.

Authors:  Roberto Jose Diaz; Brian Golbourn; Maryam Shekarforoush; Christian A Smith; James T Rutka
Journal:  J Neurooncol       Date:  2012-03-01       Impact factor: 4.130

4.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.

Authors:  Shideng Bao; Qiulian Wu; Roger E McLendon; Yueling Hao; Qing Shi; Anita B Hjelmeland; Mark W Dewhirst; Darell D Bigner; Jeremy N Rich
Journal:  Nature       Date:  2006-10-18       Impact factor: 49.962

5.  Mitotic drug targets.

Authors:  Phillip Kaestner; Holger Bastians
Journal:  J Cell Biochem       Date:  2010-10-01       Impact factor: 4.429

6.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

Authors:  Roel G W Verhaak; Katherine A Hoadley; Elizabeth Purdom; Victoria Wang; Yuan Qi; Matthew D Wilkerson; C Ryan Miller; Li Ding; Todd Golub; Jill P Mesirov; Gabriele Alexe; Michael Lawrence; Michael O'Kelly; Pablo Tamayo; Barbara A Weir; Stacey Gabriel; Wendy Winckler; Supriya Gupta; Lakshmi Jakkula; Heidi S Feiler; J Graeme Hodgson; C David James; Jann N Sarkaria; Cameron Brennan; Ari Kahn; Paul T Spellman; Richard K Wilson; Terence P Speed; Joe W Gray; Matthew Meyerson; Gad Getz; Charles M Perou; D Neil Hayes
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

7.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

8.  Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution.

Authors:  S G M Piccirillo; R Combi; L Cajola; A Patrizi; S Redaelli; A Bentivegna; S Baronchelli; G Maira; B Pollo; A Mangiola; F DiMeco; L Dalprà; A L Vescovi
Journal:  Oncogene       Date:  2009-03-16       Impact factor: 9.867

9.  Cancer-Specific requirement for BUB1B/BUBR1 in human brain tumor isolates and genetically transformed cells.

Authors:  Yu Ding; Christopher G Hubert; Jacob Herman; Philip Corrin; Chad M Toledo; Kyobi Skutt-Kakaria; Julio Vazquez; Ryan Basom; Bin Zhang; Jennifer K Risler; Steven M Pollard; Do-Hyun Nam; Jeffery J Delrow; Jun Zhu; Jeongwu Lee; Jennifer DeLuca; James M Olson; Patrick J Paddison
Journal:  Cancer Discov       Date:  2012-11-15       Impact factor: 39.397

10.  The accuracy of survival time prediction for patients with glioma is improved by measuring mitotic spindle checkpoint gene expression.

Authors:  Li Bie; Gang Zhao; Pui Cheng; Gaelle Rondeau; Steffen Porwollik; Yan Ju; Xiao-Qin Xia; Michael McClelland
Journal:  PLoS One       Date:  2011-10-12       Impact factor: 3.240
  10 in total
  5 in total

1.  High copy number variations, particular transcription factors, and low immunity contribute to the stemness of prostate cancer cells.

Authors:  Zao Dai; Ping Liu
Journal:  J Transl Med       Date:  2021-05-13       Impact factor: 5.531

2.  CDC20 maintains tumor initiating cells.

Authors:  Qi Xie; Qiulian Wu; Stephen C Mack; Kailin Yang; Leo Kim; Christopher G Hubert; William A Flavahan; Chengwei Chu; Shideng Bao; Jeremy N Rich
Journal:  Oncotarget       Date:  2015-05-30

3.  Integrated mRNAseq and microRNAseq data analysis for grade III gliomas.

Authors:  Junqiang Dai; Zhitong Bing; Yinian Zhang; Qiao Li; Liang Niu; Wentao Liang; Guoqiang Yuan; Lei Duan; Hang Yin; Yawen Pan
Journal:  Mol Med Rep       Date:  2017-09-20       Impact factor: 2.952

4.  Construction of Potential Gene Expression and Regulation Networks in Prostate Cancer Using Bioinformatics Tools.

Authors:  Heyu Liu; Lirong Li; Yuan Fan; Yaping Lu; Changhong Zhu; Wei Xia
Journal:  Oxid Med Cell Longev       Date:  2021-08-31       Impact factor: 6.543

5.  Identification of Prognostic Markers and Potential Therapeutic Targets in Gastric Adenocarcinoma by Machine Learning Based on mRNAsi Index.

Authors:  Si Hong Guo; Li Ma; Jie Chen
Journal:  J Oncol       Date:  2022-09-30       Impact factor: 4.501
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.